key: cord-0732458-j99uvku1
authors: Pean de Ponfilly, G.; Pilmis, B.; El Kaibi, I.; Castreau, N.; Laplanche, S.; Le Monnier, A.
title: Is Second dose of vaccination useful in previously SARS-CoV-2 infected Health Care Workers?
date: 2021-06-28
journal: nan
DOI: 10.1101/2021.06.22.21257103
sha: e01db8feab9ad08ca1e10208be1d9416c2c7268e
doc_id: 732458
cord_uid: j99uvku1

Vaccines are the most important public health measure to protect people from COVID-19 worldwide. In addition, healthcare workers account for a large number of infected people. Then, protecting this population from COVID-19 seems crucial in the preservation of healthcare systems. In a context of few doses available, serological assays could be useful to decide whether one or two doses are needed. Our results show that a first dose of BNT162b2 mRNA vaccine seems to act as a boost after SARS-CoV-2 infection in healthcare workers with a previous SARS-CoV-2 infection and a second dose might not be required.

Vaccines are the most important public health measure to protect people from COVID-19 16 worldwide. In addition, healthcare workers account for a large number of infected people. 17 Then, protecting this population from COVID-19 seems crucial in the preservation of 18 healthcare systems. In a context of few doses available, serological assays could be useful to 19 decide whether one or two doses are needed. Our results show that a first dose of BNT162b2 20 mRNA vaccine seems to act as a boost after SARS-CoV-2 infection in healthcare workers with 21 a previous SARS-CoV-2 infection and a second dose might not be required. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 28, 2021.

Since the early 2020, a large pandemic due to the new and emergent coronavirus (SARS-CoV-34 2) spreads all over the world. While some countries have been able to contain the pandemic 35 with a combination of public health measures (extensive testing followed by isolation and (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 28, 2021. Kinetics of natural anti-Spike antibody levels decrease more or less rapidly according to initial 119 level of IgG produced. In some cases, anti-Spike antibodies become undetectable beyond six 120 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 28, 2021. ; https://doi.org/10.1101/2021.06.22.21257103 doi: medRxiv preprint or eight months for some HCWS or some patients [7, 8] . This also raises the question of the 121 durability of the antibodies produced either after prime or boosted vaccination as for COVID-122 19 course and the impact of high initial antibodies levels. 123 Our study provides additional information on the positioning and usefulness of serology in the 124 COVID-19 vaccine strategy in order to maximize coverage and impact. 125 126 Acknowledgement: 127 We thank all colleagues who accept to participate to this study, in particular staff of the 

Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and 133 necessary measures for global immunity

Nosocomial 136 transmission and outbreaks of coronavirus disease 2019: the need to protect both 137 patients and healthcare workers

Reported Nosocomial Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 in 141

Stratégie de vaccination contre le SARS-CoV-2 : Vaccination des personnes ayant un 144 antécédent de Covid-19

Health-Related Workplace Absenteeism Among Workers in Essential Critical 147

Infrastructure Occupations During the COVID-19 Pandemic -United States

COVID-19-151 neutralizing antibodies predict disease severity and survival

Immunological memory to 154 SARS-CoV-2 assessed for up to 8 months after infection

All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 28, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 28, 2021. ; https://doi.org/10.1101/2021.06.22.21257103 doi: medRxiv preprint